Reduced Levels of Norepinephrine Transporters in the Depression

Journal of Neuroscience 17, 8451-8458 DOI: 10.1523/jneurosci.17-21-08451.1997

Citation Report

#	Article	IF	CITATIONS
1	REM sleep deprivation increases the levels of tyrosine hydroxylase and norepinephrine transporter mRNA in the locus coeruleus. Molecular Brain Research, 1998, 57, 235-240.	2.3	68
2	New views of biogenic amine transporter function: implications for neuropsychopharmacology. International Journal of Neuropsychopharmacology, 1999, 2, 305-320.	2.1	23
3	Transcriptional activity in the brain during sleep deprivation. Annals of Medicine, 1999, 31, 146-151.	3.8	3
5	Transient Depressive Relapse Induced by Catecholamine Depletion. Archives of General Psychiatry, 1999, 56, 395.	12.3	113
6	A Previously Undescribed Intron and Extensive 5′ Upstream Sequence, but Not Phox2a-mediated Transactivation, Are Necessary for High Level Cell Type-specific Expression of the Human Norepinephrine Transporter Gene. Journal of Biological Chemistry, 1999, 274, 6507-6518.	3.4	93
7	Tyrosine hydroxylase immunoreactivity in the locus coeruleus is reduced in depressed non-suicidal patients but normal in depressed suicide patients. European Archives of Psychiatry and Clinical Neuroscience, 1999, 249, 212-219.	3.2	54
8	Tyrosine hydroxylase mRNA is increased in old age and norepinephrine uptake transporter mRNA is decreased in middle age in locus coeruleus of Brown–Norway rats. Brain Research, 1999, 826, 143-147.	2.2	37
9	Quantitative distribution of monoamine oxidase A in brainstem monoamine nuclei is normal in major depression. Brain Research, 1999, 847, 71-79.	2.2	34
10	Brain Noradrenergic Receptors in Major Depression and Schizophrenia. Neuropsychopharmacology, 1999, 21, 69-81.	5.4	64
11	Increased activity of surviving locus ceruleus neurons in Alzheimer's disease. Annals of Neurology, 1999, 45, 82-91.	5.3	139
12	Norepinephrine transporter gene polymorphism is not associated with susceptibility to major depression. Psychiatry Research, 1999, 87, 1-5.	3.3	56
13	Morphometric evidence for neuronal and glial prefrontal cell pathology in major depressionâ^—â^—See accompanying Editorial, in this issue Biological Psychiatry, 1999, 45, 1085-1098.	1.3	1,395
14	Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biological Psychiatry, 1999, 46, 1219-1233.	1.3	254
15	Elevated levels of tyrosine hydroxylase in the locus coeruleus in major depression. Biological Psychiatry, 1999, 46, 1275-1286.	1.3	129
16	Lack of Association Between Depression and Loss of Neurons in the Locus Coeruleus in Alzheimer Disease. Archives of General Psychiatry, 1999, 56, 45.	12.3	61
17	Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depression and Anxiety, 2000, 12, 2-19.	4.1	746
18	Norepinephrine Uptake Sites in the Locus Coeruleus of Rat Lines Selectively Bred for High and Low Alcohol Preference: A Quantitative Autoradiographic Binding Study Using [3H]-Tomoxetine. Alcoholism: Clinical and Experimental Research, 2000, 24, 588-594.	2.4	19
19	Autoradiographic Comparison of [3H]-Clonidine Binding to Non-Adrenergic Sites and α2-Adrenergic Receptors in Human Brain. Neuropsychopharmacology, 2000, 23, 697-708.	5.4	16

#	Article	IF	CITATIONS
20	Brain alterations in depression. Acta Neuropsychiatrica, 2000, 12, 54-58.	2.1	5
21	Cocaine and Antidepressant-Sensitive Biogenic Amine Transporters Exist in Regulated Complexes with Protein Phosphatase 2A. Journal of Neuroscience, 2000, 20, 7571-7578.	3.6	192
22	Molecular Abnormalities in Brains of Depressed Patients. Neuroscientist, 2000, 6, 401-410.	3.5	0
23	The Ups and Downs of Neurotransmitter Transporters. Neuroscientist, 2000, 6, 199-207.	3.5	13
24	The serotonin transporter in the midbrain of suicide victims with major depression. Biological Psychiatry, 2000, 47, 1015-1024.	1.3	73
25	Major Depressive Disorder. Neuron, 2000, 28, 335-341.	8.1	486
26	Histopathology of the prefrontal cortex in major depression: what does it tell us about dysfunctional monoaminergic circuits?. Progress in Brain Research, 2000, 126, 397-412.	1.4	80
27	Immunolocalization of the cocaine- and antidepressant-sensitive l-norepinephrine transporter. Journal of Comparative Neurology, 2000, 420, 211-232.	1.6	225
28	Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biological Psychiatry, 2000, 48, 766-777.	1.3	750
29	Neuropathology of bipolar disorder. Biological Psychiatry, 2000, 48, 486-504.	1.3	127
30	Effects of chronic antidepressant treatments on 5-HT and NA transporters in rat brain: an autoradiographic study. Neurochemistry International, 2001, 38, 63-74.	3.8	65
31	Depression as a spreading adjustment disorder of monoaminergic neurons: a case for primary implication of the locus coeruleus. Brain Research Reviews, 2001, 38, 79-128.	9.0	141
32	Function and Regulation of Monoamine Transporters: Focus on the Norepinephrine Transporter. CNS Spectrums, 2001, 6, 671-678.	1.2	3
33	Noradrenergic Pathology in Psychiatric Disorders: Postmortem Studies. CNS Spectrums, 2001, 6, 697-703.	1.2	18
34	Basal limbic system alteration in major depression: a hypothesis supported by transcranial sonography and MRI findings. International Journal of Neuropsychopharmacology, 2001, 4, 21-31.	2.1	70
35	Effects of Long-term Cigarette Smoking on the Human Locus Coeruleus. Archives of General Psychiatry, 2001, 58, 821.	12.3	51
36	Neuroanatomical studies on bipolar disorder. British Journal of Psychiatry, 2001, 178, s142-s147.	2.8	51
37	Understanding the neurobiology of suicidal behavior. Depression and Anxiety, 2001, 14, 164-176.	4.1	82

#	ARTICLE	IF	Citations
38	Assessment of the Serotonin and Norepinephrine Reuptake Blocking Properties of Duloxetine in Healthy Subjects. Neuropsychopharmacology, 2001, 24, 511-521.	5.4	97
39	Correlation between Platelet α ₂ -Adrenoreceptors and Symptom Severity in Major Depression. Neuropsychobiology, 2001, 44, 122-125.	1.9	9
40	Genetic or acquired deficits in the norepinephrine transporter: current understanding of clinical implications. Expert Reviews in Molecular Medicine, 2001, 3, 1-10.	3.9	27
41	An E-box Motif Residing in the Exon/Intron 1 Junction Regulates Both Transcriptional Activation and Splicing of the Human Norepinephrine Transporter Gene. Journal of Biological Chemistry, 2001, 276, 24797-24805.	3.4	17
42	A Polymorphism of the Norepinephrine Transporter Gene in Bipolar Disorder and Schizophrenia: Lack of Association. Neuropsychobiology, 2002, 45, 182-185.	1.9	28
43	The neuropathology of primary mood disorder. Brain, 2002, 125, 1428-1449.	7.6	289
44	Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Molecular Psychiatry, 2002, 7, 254-275.	7.9	1,121
45	Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biological Psychiatry, 2002, 52, 740-748.	1.3	157
46	Monoamine transporter gene structure and polymorphisms in relation to psychiatric and other complex disorders. Pharmacogenomics Journal, 2002, 2, 217-235.	2.0	138
47	Exercise and the Treatment of Clinical Depression in Adults. Sports Medicine, 2002, 32, 741-760.	6.5	357
48	Chronic substance P (NK1) receptor antagonist and conventional antidepressant treatment increases burst firing of monoamine neurones in the locus coeruleus. Neuroscience, 2002, 109, 609-617.	2.3	73
49	Divergent endocrine abnormalities in melancholic and atypical depression: clinical and pathophysiologic implications. Endocrinology and Metabolism Clinics of North America, 2002, 31, 37-62.	3.2	97
50	Neurochemistry. , 0, , 397-401.		0
51	[3H]Tiagabine binding to GABA transporter-1 (GAT-1) in suicidal depression. Journal of Affective Disorders, 2002, 71, 29-33.	4.1	21
52	Regulation of norepinephrine transporter abundance by catecholamines and desipramine in vivo. Brain Research, 2002, 946, 239-246.	2.2	51
53	Identification of a Naturally Occurring Polymorphism in the Promoter Region of the Norepinephrine Transporter and Analysis in Major Depression. Neuropsychopharmacology, 2002, 26, 489-493.	5.4	93
54	Effects of desipramine treatment on norepinephrine transporter gene expression in the cultured SK-N-BE(2)M17 cells and rat brain tissue. Journal of Neurochemistry, 2002, 82, 146-153.	3.9	28
55	Functional expression of the norepinephrine transporter in cultured rat astrocytes. Journal of Neurochemistry, 2002, 84, 136-144.	3.9	72

#	Article	IF	CITATIONS
56	Downâ€Regulation of the Human Norepinephrine Transporter in Intact 293â€hNET Cells Exposed to Desipramine. Journal of Neurochemistry, 1998, 70, 1547-1555.	3.9	49
57	Neurotransmitter receptor-mediated activation of G-proteins in brains of suicide victims with mood disorders: selective supersensitivity of α2A-adrenoceptors. Molecular Psychiatry, 2002, 7, 755-767.	7.9	96
58	Serotonin transporter and MAO-B levels in monoamine nuclei of the human brainstem are normal in major depression. Journal of Psychiatric Research, 2003, 37, 387-397.	3.1	34
59	Differential expression of α2-adrenoceptor vs. imidazoline binding sites in postmortem orbitofrontal cortex and amygdala of depressed subjects. Journal of Psychiatric Research, 2003, 37, 399-409.	3.1	10
60	Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter. Journal of Psychiatric Research, 2003, 37, 357-373.	3.1	328
61	Ultrastructural localization of the norepinephrine transporter in superficial and deep layers of the rat prelimbic prefrontal cortex and its spatial relationship to probable dopamine terminals. Journal of Comparative Neurology, 2003, 466, 478-494.	1.6	96
62	Wolfram syndrome and suicide: Evidence for a role of WFS1 in suicidal and impulsive behavior. American Journal of Medical Genetics Part A, 2003, 119B, 108-113.	2.4	45
63	Increased corticotropin-releasing hormone immunoreactivity in monoamine-containing pontine nuclei of depressed suicide men. Molecular Psychiatry, 2003, 8, 324-332.	7.9	135
64	Plasma membrane monoamine transporters: structure, regulation and function. Nature Reviews Neuroscience, 2003, 4, 13-25.	10.2	846
65	Elevated agonist binding to α2-adrenoceptors in the locus coeruleus in major depression. Biological Psychiatry, 2003, 53, 315-323.	1.3	123
65 66	Elevated agonist binding to α2-adrenoceptors in the locus coeruleus in major depression. Biological Psychiatry, 2003, 53, 315-323. Common pathogenic mechanisms between depression and epilepsy: an experimental perspective. Epilepsy and Behavior, 2003, 4, 14-24.	1.3	123 102
65 66 67	Elevated agonist binding to α2-adrenoceptors in the locus coeruleus in major depression. Biological Psychiatry, 2003, 53, 315-323. Common pathogenic mechanisms between depression and epilepsy: an experimental perspective. Epilepsy and Behavior, 2003, 4, 14-24. Cortical alpha-adrenoceptor downregulation by tricyclic antidepressants in the rat brain. Neurochemistry International, 2003, 43, 603-609.	1.3 1.7 3.8	123 102 48
65666768	Elevated agonist binding to α2-adrenoceptors in the locus coeruleus in major depression. Biological Psychiatry, 2003, 53, 315-323.Common pathogenic mechanisms between depression and epilepsy: an experimental perspective. Epilepsy and Behavior, 2003, 4, 14-24.Cortical alpha-adrenoceptor downregulation by tricyclic antidepressants in the rat brain. Neurochemistry International, 2003, 43, 603-609.Specific in vivo binding to the norepinephrine transporter demonstrated with the PET radioligand, (S,S)-[11C]MeNER. Nuclear Medicine and Biology, 2003, 30, 707-714.	1.3 1.7 3.8 0.6	123 102 48 74
 65 66 67 68 69 	Elevated agonist binding to α2-adrenoceptors in the locus coeruleus in major depression. Biological Psychiatry, 2003, 53, 315-323.Common pathogenic mechanisms between depression and epilepsy: an experimental perspective. Epilepsy and Behavior, 2003, 4, 14-24.Cortical alpha-adrenoceptor downregulation by tricyclic antidepressants in the rat brain. Neurochemistry International, 2003, 43, 603-609.Specific in vivo binding to the norepinephrine transporter demonstrated with the PET radioligand, (S,S)-[11C]MeNER. Nuclear Medicine and Biology, 2003, 30, 707-714.Inhibition of the Norepinephrine Transporter by the Venom Peptide χ-MrIA. Journal of Biological Chemistry, 2003, 278, 40317-40323.	1.3 1.7 3.8 0.6 3.4	123 102 48 74 60
 65 66 67 68 69 70 	Elevated agonist binding to α2-adrenoceptors in the locus coeruleus in major depression. Biological Psychiatry, 2003, 53, 315-323.Common pathogenic mechanisms between depression and epilepsy: an experimental perspective. Epilepsy and Behavior, 2003, 4, 14-24.Cortical alpha-adrenoceptor downregulation by tricyclic antidepressants in the rat brain. Neurochemistry International, 2003, 43, 603-609.Specific in vivo binding to the norepinephrine transporter demonstrated with the PET radioligand, (\$,\$)-[11C]MeNER. Nuclear Medicine and Biology, 2003, 30, 707-714.Inhibition of the Norepinephrine Transporter by the Venom Peptide ·-MrIA. Journal of Biological Chemistry, 2003, 278, 40317-40323.Elevated Concentrations of CRF in the Locus Coeruleus of Depressed Subjects. Neuropsychopharmacology, 2003, 28, 1328-1335.	1.3 1.7 3.8 0.6 3.4 5.4	123 102 48 74 60 133
 65 66 67 68 69 70 71 	Elevated agonist binding to 1±2-adrenoceptors in the locus coeruleus in major depression. Biological Psychiatry, 2003, 53, 315-323.Common pathogenic mechanisms between depression and epilepsy: an experimental perspective. Epilepsy and Behavior, 2003, 4, 14-24.Cortical alpha-adrenoceptor downregulation by tricyclic antidepressants in the rat brain. Neurochemistry International, 2003, 43, 603-609.Specific in vivo binding to the norepinephrine transporter demonstrated with the PET radioligand, (S,S)-[11C]MeNER. Nuclear Medicine and Biology, 2003, 30, 707-714.Inhibition of the Norepinephrine Transporter by the Venom Peptide 1±-MrIA. Journal of Biological Chemistry, 2003, 278, 40317-40323.Elevated Concentrations of CRF in the Locus Coeruleus of Depressed Subjects. Neuropsychopharmacology, 2003, 28, 1328-1335.Nitrous Oxide Attenuates Pressor but Augments Norepinephrine Response to Laryngoscopy and Endotracheal Intubation. Anesthesia and Analgesia, 2003, 96, 1516-1521.	1.3 1.7 3.8 0.6 3.4 5.4	123 102 48 74 60 133
 65 66 67 68 69 70 71 72 	Elevated agonist binding to 1±2-adrenoceptors in the locus coeruleus in major depression. Biological Psychiatry, 2003, 53, 315-323.Common pathogenic mechanisms between depression and epilepsy: an experimental perspective. Epilepsy and Behavior, 2003, 4, 14-24.Cortical alpha-adrenoceptor downregulation by tricyclic antidepressants in the rat brain. Neurochemistry International, 2003, 43, 603-609.Specific in vivo binding to the norepinephrine transporter demonstrated with the PET radioligand, (\$,\$)-[11C]MeNER. Nuclear Medicine and Biology, 2003, 30, 707-714.Inhibition of the Norepinephrine Transporter by the Venom Peptide 1±-MrIA. Journal of Biological Chemistry, 2003, 278, 40317-40323.Elevated Concentrations of CRF in the Locus Coeruleus of Depressed Subjects. Neuropsychopharmacology, 2003, 28, 1328-1335.Nitrous Oxide Attenuates Pressor but Augments Norepinephrine Response to Laryngoscopy and Endotracheal Intubation. Anesthesia and Analgesia, 2003, 96, 1516-1521.Correlates of Generalized Anxiety and Panic Attacks in Dystonia and Parkinson Disease. Cognitive and Behavioral Neurology, 2003, 16, 225-233.	1.3 1.7 3.8 0.6 3.4 5.4 2.2 0.9	123 102 48 74 60 133 5 71

#	Article	IF	CITATIONS
74	The neuropathology of mood disorders. , 2003, , 291-307.		1
75	A Regulated Interaction of Syntaxin 1A with the Antidepressant-Sensitive Norepinephrine Transporter Establishes Catecholamine Clearance Capacity. Journal of Neuroscience, 2003, 23, 1697-1709.	3.6	150
76	Regional Brain Metabolic Correlates of α-Methylparatyrosine–Induced Depressive Symptoms. JAMA - Journal of the American Medical Association, 2003, 289, 3125.	7.4	111
77	Organization of Human Brain Stem Nuclei. , 2004, , 267-320.		21
78	Association between Norepinephrine Transporter Gene Polymorphism and Major Depression. Neuropsychobiology, 2004, 49, 174-177.	1.9	66
79	Differential DSM-III Psychiatric Disorder Prevalence Profiles in Dystonia and Parkinson's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2004, 16, 29-36.	1.8	59
80	Regulated Internalization and Phosphorylation of the Native Norepinephrine Transporter in Response to Phorbol Esters. Journal of Biological Chemistry, 2004, 279, 19315-19326.	3.4	131
81	Low nNOS protein in the locus coeruleus in major depression. Journal of Neurochemistry, 2004, 91, 1057-1066.	3.9	74
82	In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Molecular Psychiatry, 2004, 9, 326-357.	7.9	553
83	Chlorotoxin-mediated disinhibition of noradrenergic locus coeruleus neurons using a conditional transgenic approach. Brain Research, 2004, 1016, 20-32.	2.2	10
84	PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain. Synapse, 2004, 53, 57-67.	1.2	105
85	Postmortem serotonin (5-HT) concentrations in the cerebrospinal fluid of medicolegal cases. Forensic Science International, 2004, 142, 211-219.	2.2	13
86	Positive Association between <i>T-182C</i> Polymorphism in the Norepinephrine Transporter Gene and Susceptibility to Major Depressive Disorder in a Japanese Population. Neuropsychobiology, 2004, 50, 301-304.	1.9	59
87	Update on PET radiopharmaceuticals: life beyond fluorodeoxyglucose. Radiologic Clinics of North America, 2004, 42, 1033-1053.	1.8	37
88	Synthesis and biological evaluation of [11C]talopram and [11C]talsupram: candidate PET ligands for the norepinephrine transporter. Nuclear Medicine and Biology, 2004, 31, 705-718.	0.6	38
89	Evaluation of radioiodinated (R)-N-methyl-3-(2-iodophenoxy)-3-phenylpropanamine as a ligand for brain norepinephrine transporter imaging. Nuclear Medicine and Biology, 2004, 31, 147-153.	0.6	24
90	Selective binding of 2-[1251]iodo-nisoxetine to norepinephrine transporters in the brain. Nuclear Medicine and Biology, 2004, 31, 533-541.	0.6	35
91	Life Stress, Genes, and Depression: Multiple Pathways Lead to Increased Risk and New Opportunities for Intervention Science Signaling 2004, 2004, re5	3.6	302

ARTICLE IF CITATIONS # Whole-body biodistribution, radiation dosimetry estimates for the PET norepinephrine transporter probe (S,S)-[18F]FMeNER-D2 in non-human primates. Nuclear Medicine Communications, 2005, 26, 18 92 1.1 695-700. Norepinephrine transporter immunoblotting and radioligand binding in cocaine abusers. Journal of 94 2.5 Neuroscience Methods, 2005, 143, 79-85. Synthesis and C-11 labeling of three potent norepinephrine transporter selective ligands 95 ((R)-nisoxetine, lortalamine, and oxaprotiline) for comparative PET studies in baboons. Bioorganic and 3.014 Medicinal Chemistry, 2005, 13, 4658-4666. Comparative evaluation of positron emission tomography radiotracers for imaging the norepinephrine transporter: (S,S) and (R,R) enantiomers of reboxetine analogs ([11C]methylreboxetine,) Tj ETQq1 1 0.784314 rgBT 96 2005, 94, 337-351 Single and repeated immobilization stress differentially trigger induction and phosphorylation of 97 several transcription factors and mitogen-activated protein kinases in the rat locus coeruleus. 3.9 64 Journal of Neurochemistry, 2005, 95, 484-498. $\hat{I}\pm 2$ -Adrenoceptor involvement in the in vitro inhibitory effect of citalopram on a subpopulation of rat 3.5 locus coeruleus neurons. European Journal of Pharmacology, 2005, 517, 51-58. Noradrenaline transporter and its turnover rate are decreased in blood lymphocytes of patients with 99 2.314 major depression. Journal of Neuroimmunology, 2005, 170, 134-140. Protein kinase C substrate activators: potential as novel antidepressants. Drug Development Research, 100 2.9 2005, 65, 156-169. Chronic treatment with duloxetine is necessary for an anxiolytic-like response in the mouse zero 101 3.1 39 maze: the role of the serotonin transporter. Psychopharmacology, 2005, 181, 741-750. 104 Conotoxins as Research Tools and Drug Leads. Current Protein and Peptide Science, 2005, 6, 221-240. 1.4 Elevated Levels of the NR2C Subunit of the NMDA Receptor in the Locus Coeruleus in Depression. 105 5.468 Neuropsychopharmacology, 2005, 30, 1557-1567. Single Nucleotide Polymorphisms in the Human Norepinephrine Transporter Gene Affect Expression, Trafficking, Antidepressant Interaction, and Protein Kinase C Regulation. Molecular Pharmacology, 2.3 2005, 68, 457-466. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic 107 7.6 905 system. Brain, 2005, 128, 1314-1322. Post-mortem human brain autoradiography of the norepinephrine transporter using 64 (S,S)-[18F]FMeNER-D2. European Neuropsychopharmacology, 2005, 15, 517-520. Proteomic analysis of human norepinephrine transporter complexes reveals associations with protein 109 phosphatase 2A anchoring subunit and 14-3-3 proteins. Biochemical and Biophysical Research 2.135 Communications, 2005, 333, 671-678. Development of the norepinephrine transporter in the rat CNS. Neuroscience, 2005, 130, 107-117. Synthesis and biological evaluation of trans-3-phenyl-1-indanamines as potential norepinephrine 111 0.6 4 transporter imaging agents. Nuclear Medicine and Biology, 2005, 32, 593-605. New-generation radiotracers for nAChR and NET. Nuclear Medicine and Biology, 2005, 32, 707-718.

#	Article	IF	CITATIONS
113	Regulation of monoamine transporters: Influence of psychostimulants and therapeutic antidepressants. AAPS Journal, 2005, 7, E728-E738.	4.4	110
114	Suicide Brain Is Associated with Decreased Expression of Neurotrophins. Biological Psychiatry, 2005, 58, 315-324.	1.3	103
116	Imaging in Parkinson's Disease: The Role of Monoamines in Behavior. Biological Psychiatry, 2006, 59, 908-918.	1.3	136
117	Further Structural Exploration of Trisubstituted Asymmetric Pyran Derivatives (2S,4R,5R)-2-Benzhydryl-5-benzylamino-tetrahydropyran-4-ol and Their Corresponding Disubstituted (3S,6S) Pyran Derivatives:Â A Proposed Pharmacophore Model for High-Affinity Interaction with the Dopamine, Serotonin, and Norepinephrine Transporters. Journal of Medicinal Chemistry, 2006, 49,	6.4	26
118	42394247 Effects of Genes and Stress on the Neurobiology of Depression. International Review of Neurobiology, 2006, 73, 153-189.	2.0	27
119	Attenuation of the norepinephrine transporter activity and trafficking via interactions with α-synuclein. European Journal of Neuroscience, 2006, 24, 3141-3152.	2.6	53
120	The norepinephrine transporter and its regulation. Journal of Neurochemistry, 2006, 97, 310-333.	3.9	116
121	KCl stimulation increases norepinephrine transporter function in PC12 cells. Journal of Neurochemistry, 2006, 98, 1521-1530.	3.9	20
122	The Promises and Pitfalls of Reboxetine. CNS Neuroscience & Therapeutics, 2003, 9, 327-342.	4.0	32
123	Synthesis and evaluation of radioiodinated (S,S)-2-(α-(2-iodophenoxy)benzyl)morpholine for imaging brain norepinephrine transporter. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 639-647.	6.4	26
124	Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2. Psychopharmacology, 2006, 188, 119-127.	3.1	71
125	Normal [3H]flunitrazepam binding to GABAA receptors in the locus coeruleus in major depression and suicide. Brain Research, 2006, 1125, 138-146.	2.2	17
126	Synthesis and PET evaluation of (R)-[S-methyl-11C]thionisoxetine, a candidate radioligand for imaging brain norepinephrine transporters. Journal of Labelled Compounds and Radiopharmaceuticals, 2006, 49, 1007-1019.	1.0	14
128	Effect of Antidepressant Drugs in Mice Lacking the Norepinephrine Transporter. Neuropsychopharmacology, 2006, 31, 2424-2432.	5.4	64
129	PET Imaging of Norepinephrine Transporters. Current Pharmaceutical Design, 2006, 12, 3831-45.	1.9	41
130	Monoamine Receptors and Signal Transduction Mechanisms in Suicide. Current Psychiatry Reviews, 2006, 2, 51-75.	0.9	7
131	Neurotransmitter Imaging. , 2006, , 385-403.		2
133	Elevated Monoamine Oxidase A Levels in the Brain. Archives of General Psychiatry, 2006, 63, 1209.	12.3	507

#	Article	IF	CITATIONS
134	Neuroimaging of the Serotonin Transporter: Possibilities and Pitfalls. Current Psychiatry Reviews, 2006, 2, 111-149.	0.9	25
135	Phosphorylation of the Norepinephrine Transporter at Threonine 258 and Serine 259 Is Linked to Protein Kinase C-mediated Transporter Internalization. Journal of Biological Chemistry, 2006, 281, 23326-23340.	3.4	68
136	A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19164-19169.	7.1	131
137	The Functional Impact of SLC6 Transporter Genetic Variation. Annual Review of Pharmacology and Toxicology, 2007, 47, 401-441.	9.4	114
138	Development of Radioligands for Imaging of Brain Norepinephrine Transporters In Vivo with Positron Emission Tomography. Current Topics in Medicinal Chemistry, 2007, 7, 1806-1816.	2.1	20
139	Association study of the norepinephrine transporter gene polymorphisms and bipolar disorder in Han Chinese population. World Journal of Biological Psychiatry, 2007, 8, 188-195.	2.6	7
141	Differential physiological effects of a low dose and high doses of venlafaxine in major depression. International Journal of Neuropsychopharmacology, 2007, 10, 51.	2.1	115
142	Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: problems and progress. Nuclear Medicine and Biology, 2007, 34, 667-679.	0.6	65
143	LeuT-Desipramine Structure Reveals How Antidepressants Block Neurotransmitter Reuptake. Science, 2007, 317, 1390-1393.	12.6	317
144	Calcium-dependent interactions of the human norepinephrine transporter with syntaxin 1A. Molecular and Cellular Neurosciences, 2007, 34, 251-260.	2.2	29
147	Noradrenergic Function in Suicide. Archives of Suicide Research, 2007, 11, 235-246.	2.3	25
149	Norepinephrine Transporter Gene Variation Modulates Acute Response to d-Amphetamine. Biological Psychiatry, 2007, 61, 1296-1305.	1.3	39
150	The central noradrenergic system: an overview. African Journal of Psychiatry, 2007, 10, 135-41.	0.1	10
151	Actions of antidepressant and other drugs on norepinephrine systems. , 0, , 515-534.		0
152	The norepinephrine transporter and regulation of synaptic transmission. , 2007, , 119-154.		0
153	Neuropathology of central norepinephrine in psychiatric disorders: postmortem research. , 2007, , 341-362.		7
154	Synthesis of 11C-labelled (R)-OHDMI and CFMME and their evaluation as candidate radioligands for imaging central norepinephrine transporters with PET. Bioorganic and Medicinal Chemistry, 2007, 15, 616-625.	3.0	14
155	Synthesis of enantiomerically pure milnacipran analogs and inhibition of dopamine, serotonin, and norepinephrine transporters. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 2834-2837.	2.2	25

#	Article	IF	CITATIONS
156	Synthesis and biological evaluation of 2l̂²,3l̂±-(substituted phenyl)nortropanes as potential norepinephrine transporter imaging agents. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 3044-3047.	2.2	3
157	Regulation of the norepinephrine transporter by αâ€synucleinâ€mediated interactions with microtubules. European Journal of Neuroscience, 2007, 26, 1509-1520.	2.6	39
159	Tyrosine hydroxylase immunoreactivity in the locus coeruleus is elevated in violent suicidal depressive patients. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 513-520.	3.2	27
160	Cloning, expression, and functional analysis of rhesus monkey trace amineâ€associated receptor 6: Evidence for lack of monoaminergic association. Journal of Neuroscience Research, 2008, 86, 3435-3446.	2.9	25
161	Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A doubleâ€blind, randomized, placeboâ€controlled study. Movement Disorders, 2008, 23, 850-857.	3.9	231
162	Functional Gene Variation in the Human Norepinephrine Transporter. Annals of the New York Academy of Sciences, 2008, 1129, 256-260.	3.8	35
163	Regulated interactions of the norepineprhine transporter by the actin and microtubule cytoskeletons. Journal of Neurochemistry, 2008, 105, 1668-1682.	3.9	16
164	Reactivity of 5-HT1A receptor in adult rats after neonatal noradrenergic neurons' lesion — Implications for antidepressant-like action. Brain Research, 2008, 1239, 66-76.	2.2	10
165	Applying Neuroimaging Ligands to Study Major Depressive Disorder. Seminars in Nuclear Medicine, 2008, 38, 287-304.	4.6	52
166	(R)-N-Methyl-3-(3-1251-pyridin-2-yloxy)-3-phenylpropan-1-amine: a novel probe for norepinephrine transporters. Nuclear Medicine and Biology, 2008, 35, 43-52.	0.6	9
167	Three-dimensional quantitative structure-activity relationship (3D QSAR) and pharmacophore elucidation of tetrahydropyran derivatives as serotonin and norepinephrine transporter inhibitors. Journal of Computer-Aided Molecular Design, 2008, 22, 1-17.	2.9	14
168	Modulation of Monoamine Transporters by Common Biogenic Amines via Trace Amine-Associated Receptor 1 and Monoamine Autoreceptors in Human Embryonic Kidney 293 Cells and Brain Synaptosomes. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 629-640.	2.5	68
169	Molecular Genetics of Brain Noradrenergic Neurotransmission. , 2008, , 129-147.		0
170	Norepinephrine Transporter Regulation Mediates the Long-Term Behavioral Effects of the Antidepressant Desipramine. Neuropsychopharmacology, 2008, 33, 3190-3200.	5.4	39
172	Signatures of Depression in Non-Stationary Biometric Time Series. Computational Intelligence and Neuroscience, 2009, 2009, 1-7.	1.7	1
173	Desipramine Modulation of α-, γ-Synuclein, and the Norepinephrine Transporter in an Animal Model of Depression. Neuropsychopharmacology, 2009, 34, 987-998.	5.4	41
174	Through the looking glass: Examining neuroanatomical evidence for cellular alterations in major depression. Journal of Psychiatric Research, 2009, 43, 947-961.	3.1	129
175	Subcellular localization of the antidepressant-sensitive norepinephrine transporter. BMC Neuroscience, 2009, 10, 65.	1.9	35

#	Article	IF	CITATIONS
176	Trace amine-associated receptor 1 as a monoaminergic modulator in brain. Biochemical Pharmacology, 2009, 78, 1095-1104.	4.4	91
177	Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Research Reviews, 2009, 61, 105-123.	9.0	340
178	Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response. Psychopharmacology, 2009, 205, 409-417.	3.1	67
179	Depression and antidepressants: molecular and cellular aspects. Cellular and Molecular Life Sciences, 2009, 66, 2985-3008.	5.4	70
180	Saturated norepinephrine transporter occupancy by atomoxetine relevant to clinical doses: a rhesus monkey study with (S,S)-[18F]FMeNER-D2. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1308-1314.	6.4	23
181	Longâ€term treatment with fluoxetine induces desensitization of 5â€HT ₄ receptorâ€dependent signalling and functionality in rat brain. Journal of Neurochemistry, 2009, 110, 1120-1127.	3.9	61
182	Effects of transcription factors Phox2 on expression of norepinephrine transporter and dopamine βâ€hydroxylase in SKâ€Nâ€BE(2)C cells. Journal of Neurochemistry, 2009, 110, 1502-1513.	3.9	9
183	Brain creatine kinase activity is increased by chronic administration of paroxetine. Brain Research Bulletin, 2009, 80, 327-330.	3.0	33
184	The norepinephrine transporter gene modulates the relationship between urban/rural residency and major depressive disorder in a Chinese population. Psychiatry Research, 2009, 168, 213-217.	3.3	16
186	Desipramine induced changes in the norepinephrine transporter, α- and γ-synuclein in the hippocampus, amygdala and striatum. Neuroscience Letters, 2009, 467, 86-89.	2.1	15
187	Fluorine-18 Radiolabeled PET Tracers for Imaging Monoamine Transporters: Dopamine, Serotonin, and Norepinephrine. PET Clinics, 2009, 4, 101-128.	3.0	19
189	Differential modulation of alpha-1 adrenoceptor subtypes by antidepressants in the rat brain. Journal of Neural Transmission, 2010, 117, 1423-1430.	2.8	8
190	Emerging structure–function relationships defining monoamine NSS transporter substrate and ligand affinity. Biochemical Pharmacology, 2010, 79, 1083-1091.	4.4	29
191	Association studies of â^'3081(A/T) polymorphism of norepinephrine transporter gene with attention deficit/hyperactivity disorder in Korean population. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 691-694.	1.7	21
192	(¹⁸ Fâ€MFP3) as a potential PET imaging agent for norepinephrine transporter. Journal of Labelled Compounds and Radiopharmaceuticals, 2010, 53, 172-177.	1.0	1
194	Rab11 Supports Amphetamine-Stimulated Norepinephrine Transporter Trafficking. Journal of Neuroscience, 2010, 30, 7863-7877.	3.6	27
195	Insulin Reveals Akt Signaling as a Novel Regulator of Norepinephrine Transporter Trafficking and Norepinephrine Homeostasis. Journal of Neuroscience, 2010, 30, 11305-11316.	3.6	71
196	Chemical Delivery System of Metaiodobenzylguanidine (MIBG) to the Central Nervous System. Journal of Medicinal Chemistry, 2010, 53, 1281-1287.	6.4	20

#	Article	IF	CITATIONS
197	Reserpine-induced reduction in norepinephrine transporter function requires catecholamine storage vesicles. Neurochemistry International, 2010, 56, 760-767.	3.8	29
198	The norepinephrine transporter (NET) radioligand (S,S)-[18F]FMeNER-D2 shows significant decreases in NET density in the human brain in Alzheimer's disease: A post-mortem autoradiographic study. Neurochemistry International, 2010, 56, 789-798.	3.8	62
199	A timeline for Parkinson's disease. Parkinsonism and Related Disorders, 2010, 16, 79-84.	2.2	470
200	Comorbidity of insomnia and depression. Sleep Medicine Reviews, 2010, 14, 35-46.	8.5	371
201	Pathobiological targets of depression. Expert Opinion on Therapeutic Targets, 2011, 15, 379-400.	3.4	58
202	Discovery of Novel Selective Serotonin Reuptake Inhibitors through Development of a Protein-Based Pharmacophore. Journal of Chemical Information and Modeling, 2011, 51, 2417-2426.	5.4	27
203	Synuclein modulation of monoamine transporters. FEBS Letters, 2011, 585, 1001-1006.	2.8	64
204	The importance of norepinephrine in depression. Neuropsychiatric Disease and Treatment, 2011, 7, 9.	2.2	217
205	Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. Molecular Psychiatry, 2011, 16, 634-646.	7.9	313
206	Regulation of monoamine transporters: Role of transporter phosphorylation. , 2011, 129, 220-238.		120
207	Maternal depression and anxiety are associated with altered gene expression in the human placenta without modification by antidepressant use: Implications for fetal programming. Developmental Psychobiology, 2011, 53, 711-723.	1.6	75
208	A Second Extracellular Site Is Required for Norepinephrine Transport by the Human Norepinephrine Transporter. Molecular Pharmacology, 2012, 82, 898-909.	2.3	18
209	Neurobiology of Depression and Novel Antidepressant Drug Targets. Current Pharmaceutical Design, 2012, 18, 5791-5801.	1.9	20
210	Norepinephrine Transporter Imaging in the Brain of a Rat Model of Depression Using Radioiodinated (2S, 1±S)-2-(α-(2-iodophenoxy)benzyl)morpholine. Molecular Imaging, 2012, 11, 7290.2011.00049.	1.4	3
211	Noradrenergic Dysfunction in Depression and Suicide. Frontiers in Neuroscience, 2012, , 29-64.	0.0	19
212	Organization of Brainstem Nuclei. , 2012, , 260-327.		70
213	Synergistic tonic and phasic activity of the locus coeruleus norepinephrine (LC-NE) arousal system is required for optimal attentional performance. Metabolic Brain Disease, 2012, 27, 267-274.	2.9	118
214	α2 adrenergic receptor dysregulation in depressive disorders: Implications for the neurobiology of depression and antidepressant therapy. Neuroscience and Biobehavioral Reviews, 2012, 36, 2214-2225.	6.1	94

#	Article	IF	CITATIONS
215	Pupillometry. Perspectives on Psychological Science, 2012, 7, 18-27.	9.0	696
218	Monoamine Transporter Structure, Function, Dynamics, and Drug Discovery: A Computational Perspective. AAPS Journal, 2012, 14, 820-831.	4.4	39
219	X-ray structures of LeuT in substrate-free outward-open and apo inward-open states. Nature, 2012, 481, 469-474.	27.8	488
220	Evidence for Transcriptional Factor Dysregulation in the Dorsal Raphe Nucleus of Patients with Major Depressive Disorder. Frontiers in Neuroscience, 2012, 6, 135.	2.8	35
221	Immunohistochemical evidence for impaired nitric oxide signaling of the locus coeruleus in bipolar disorder. Brain Research, 2012, 1459, 91-99.	2.2	17
222	Association between major depressive disorder and the norepinephrine transporter polymorphisms T-182C and G1287A: A meta-analysis. Journal of Affective Disorders, 2013, 150, 23-28.	4.1	27
223	Development and automation of a novel NET-PET tracer: [11C]Me@APPI. Nuclear Medicine and Biology, 2013, 40, 295-303.	0.6	11
224	Catecholamine depletion in first-degree relatives of individuals with mood disorders: An [18F]fluorodeoxyglucose positron emission tomography study. NeuroImage: Clinical, 2013, 2, 341-355.	2.7	3
225	Recent Progress in Understanding the Pathophysiology of Post-Traumatic Stress Disorder. CNS Drugs, 2013, 27, 221-232.	5.9	78
226	Methylphenidate. CNS Drugs, 2013, 27, 1-14.	5.9	40
227	Role of Serotonin Type-1A/B (Hydroxytryptamine) Receptors in Depression Revisited. Systematic Reviews in Pharmacy (discontinued), 2013, 4, 7.	0.2	0
228	Norepinephrine transporter variant A457P knock-in mice display key features of human postural orthostatic tachycardia syndrome. DMM Disease Models and Mechanisms, 2013, 6, 1001-11.	2.4	17
229	Gene expression deficits in pontine locus coeruleus astrocytes in men with major depressive disorder. Journal of Psychiatry and Neuroscience, 2013, 38, 276-284.	2.4	84
230	The current state of play on the molecular genetics of depression. Psychological Medicine, 2013, 43, 673-687.	4.5	73
231	Altered expression of norepinephrine transporter and norepinephrine in human placenta cause pre-eclampsia through regulated trophoblast invasion. Clinical and Experimental Reproductive Medicine, 2013, 40, 12.	1.5	10
232	Invisible emotional expressions influence social judgments and pupillary responses of both depressed and non-depressed individuals. Frontiers in Psychology, 2013, 4, 291.	2.1	20
233	Effects of Acute Intracerebroventricular Microinfusions of Bupropion on Background Spike Activity of Locus Coeruleus Neurons in Rats. Neurophysiology, 2014, 46, 316-322.	0.3	1
234	Norepinephrine transporter occupancy by nortriptyline in patients with depression: a positron emission tomography study with (S,S)-[18F]FMeNER-D2. International Journal of Neuropsychopharmacology, 2014, 17, 553-560.	2.1	22

#	Article	IF	CITATIONS
235	Association between norepinephrine transporter T-182C polymorphism and major depressive disorder: A meta-analysis. Neuroscience Letters, 2014, 561, 64-68.	2.1	8
236	Depressive behavior in the forced swim test can be induced by TRPV1 receptor activity and is dependent on NMDA receptors. Pharmacological Research, 2014, 79, 21-27.	7.1	51
237	Toward a Biosignature for Suicide. American Journal of Psychiatry, 2014, 171, 1259-1277.	7.2	238
238	[11C]NS8880, a promising PET radiotracer targeting the norepinephrine transporter. Nuclear Medicine and Biology, 2014, 41, 758-764.	0.6	6
239	Omega-3 fatty acid deficient male rats exhibit abnormal behavioral activation in the forced swim test following chronic fluoxetine treatment: Association with altered 5-HT1A and alpha2A adrenergic receptor expression. Journal of Psychiatric Research, 2014, 50, 42-50.	3.1	24
240	Interactions of atenolol with alprazolam/escitalopram on anxiety, depression and oxidative stress. Pharmacology Biochemistry and Behavior, 2014, 117, 79-84.	2.9	19
241	Synthesis and in Silico Evaluation of Novel Compounds for PET-Based Investigations of the Norepinephrine Transporter. Molecules, 2015, 20, 1712-1730.	3.8	6
242	A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates. Current Neuropharmacology, 2015, 13, 324-368.	2.9	75
243	Acute Vagal Nerve Stimulation Lowers α2 Adrenoceptor Availability: Possible Mechanism of Therapeutic Action. Brain Stimulation, 2015, 8, 702-707.	1.6	34
244	Serotonin transporter (5-HTTLPR) and norepinephrine transporter (NET) gene polymorphisms: Susceptibility and treatment response of electroconvulsive therapy in treatment resistant depression. Neuroscience Letters, 2015, 590, 116-120.	2.1	17
245	Major depression and electrovestibulography. World Journal of Biological Psychiatry, 2015, 16, 334-350.	2.6	26
246	Orexin and Sleep. , 2015, , .		2
247	Molecular imaging of striatal dopamine transporters in major depression—A meta-analysis. Journal of Affective Disorders, 2015, 174, 137-143.	4.1	27
248	Withdrawal from repeated administration of a low dose of reserpine induced opposing adaptive changes in the noradrenaline and serotonin system function: A behavioral and neurochemical ex vivo and in vivo studies in the rat. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 57 146-154	4.8	9
249	The selective noradrenergic reuptake inhibitor reboxetine restores spatial learning deficits, biochemical changes, and hippocampal synaptic plasticity in an animal model of depression. Journal of Neuroscience Research, 2015, 93, 104-120.	2.9	22
250	Dentate gyrus and hilar region revisited. Behavioral and Brain Sciences, 2016, 39, e210.	0.7	2
251	Relationship between G1287A of the NET Gene Polymorphisms and Brain Volume in Major Depressive Disorder: A Voxel-Based MRI Study. PLoS ONE, 2016, 11, e0150712.	2.5	18
252	Evaluation of [¹¹ <scp>C</scp>]TAZA for amyloid β plaque imaging in postmortem human <scp>A</scp> lzheimer's disease brain region and whole body distribution in rodent PET/CT. Synapse, 2016, 70, 163-176.	1.2	12

#	Article	IF	CITATIONS
253	GANEing traction: The broad applicability of NE hotspots to diverse cognitive and arousal phenomena. Behavioral and Brain Sciences, 2016, 39, e228.	0.7	16
254	Bodily arousal differentially impacts stimulus processing and memory: Norepinephrine in interoception. Behavioral and Brain Sciences, 2016, 39, e205.	0.7	5
255	What do we GANE with age?. Behavioral and Brain Sciences, 2016, 39, e218.	0.7	2
256	Amplified selectivity in cognitive processing implements the neural gain model of norepinephrine function. Behavioral and Brain Sciences, 2016, 39, e206.	0.7	7
257	Emotionally arousing context modulates the ERP correlates of neutral picture processing: An ERP test of the GANE model. Behavioral and Brain Sciences, 2016, 39, e225.	0.7	4
258	The role of arousal in predictive coding. Behavioral and Brain Sciences, 2016, 39, e207.	0.7	11
259	Glutamate and norepinephrine interaction: Relevance to higher cognitive operations and psychopathology. Behavioral and Brain Sciences, 2016, 39, e201.	0.7	6
260	Does arousal enhance apical amplification and disamplification?. Behavioral and Brain Sciences, 2016, 39, e215.	0.7	6
261	GANEing on emotion and emotion regulation. Behavioral and Brain Sciences, 2016, 39, e211.	0.7	0
262	What BANE can offer GANE: Individual differences in function of hotspot mechanisms. Behavioral and Brain Sciences, 2016, 39, e226.	0.7	0
263	Interactions of noradrenaline and cortisol and the induction of indelible memories. Behavioral and Brain Sciences, 2016, 39, e213.	0.7	1
264	For better or worse, or for a change?. Behavioral and Brain Sciences, 2016, 39, e203.	0.7	Ο
265	Bidirectional synaptic plasticity can explain bidirectional retrograde effects of emotion on memory. Behavioral and Brain Sciences, 2016, 39, e224.	0.7	1
266	Antidepressant imipramine diminishes stress-induced inflammation in the periphery and central nervous system and related anxiety- and depressive- like behaviors. Brain, Behavior, and Immunity, 2016, 57, 293-303.	4.1	73
267	The Role of Genetic and Environmental Risk Factors in Aetiology of Suicidal Behaviour. , 2016, , 205-230.		0
268	A2 noradrenergic neurons regulate forced swim test immobility. Physiology and Behavior, 2016, 165, 339-349.	2.1	8
269	Cognitive control, dynamic salience, and the imperative toward computational accounts of neuromodulatory function. Behavioral and Brain Sciences, 2016, 39, e227.	0.7	5
270	The Fluency Amplification Model supports the GANE principle of arousal enhancement. Behavioral and Brain Sciences, 2016, 39, e204.	0.7	5

#	Article	IF	CITATIONS
271	Once more with feeling: On the explanatory limits of the GANE model and the missing role of subjective experience. Behavioral and Brain Sciences, 2016, 39, e212.	0.7	0
272	Competition elicits arousal and affect. Behavioral and Brain Sciences, 2016, 39, e220.	0.7	0
273	Effect of arousal on perception as studied through the lens of the motor correlates of sexual arousal. Behavioral and Brain Sciences, 2016, 39, e217.	0.7	1
274	Emotional memory: From affective relevance to arousal. Behavioral and Brain Sciences, 2016, 39, e216.	0.7	9
275	Effects of norepinephrine transporter gene variants on <scp>NET</scp> binding in <scp>ADHD</scp> and healthy controls investigated by <scp>PET</scp> . Human Brain Mapping, 2016, 37, 884-895.	3.6	37
276	Depressive Disorder After Pontine Ischemic Stroke: Clinicoradiologic Correlates. Journal of Neuropsychiatry and Clinical Neurosciences, 2016, 28, e1-e2.	1.8	1
277	The central nervous norepinephrine network links a diminished sense of emotional well-being to an increased body weight. International Journal of Obesity, 2016, 40, 779-787.	3.4	16
278	Ca 2+ dependent surface trafficking of norepinephrine transporters depends on threonine 30 and Ca 2+ calmodulin kinases. Journal of Chemical Neuroanatomy, 2017, 83-84, 19-35.	2.1	4
279	PET Quantification of the Norepinephrine Transporter in Human Brain with (<i>S,S</i>)- ¹⁸ F-FMeNER-D ₂ . Journal of Nuclear Medicine, 2017, 58, 1140-1145.	5.0	18
280	DNA methylation in the norepinephrine transporter gene promoter region is not associated with depression and hypertension. Clinical and Experimental Hypertension, 2017, 39, 539-545.	1.3	3
281	Changes in neural circuitry associated with depression at pre-clinical, pre-motor and early motor phases of Parkinson's disease. Parkinsonism and Related Disorders, 2017, 35, 17-24.	2.2	43
282	Norepinephrine Transporter in Major Depressive Disorder: A PET Study. American Journal of Psychiatry, 2017, 174, 36-41.	7.2	38
283	The Role of Norepinephrine and Its α-Adrenergic Receptors in the Pathophysiology and Treatment of Major Depressive Disorder and Schizophrenia: A Systematic Review. Frontiers in Psychiatry, 2017, 8, 42.	2.6	92
284	Dopamine and serotonin contribute to Paecilomyces hepiali against chronic unpredictable mild stress induced depressive behavior in Sprague Dawley rats. Molecular Medicine Reports, 2017, 16, 5675-5682.	2.4	12
285	A Positron Emission Tomography Study of Norepinephrine Transporter Occupancy and Its Correlation with Symptom Response in Depressed Patients Treated with Quetiapine XR. International Journal of Neuropsychopharmacology, 2018, 21, 108-113.	2.1	10
286	Biomarkers of Depression: Potential Diagnostic Tools. , 2018, , 35-51.		1
287	High-resolution in vivo imaging of human locus coeruleus by magnetization transfer MRI at 3T and 7T. NeuroImage, 2018, 168, 427-436.	4.2	104
288	Conducting polymer-based electrochemical biosensors for neurotransmitters: A review. Biosensors and Bioelectronics, 2018, 102, 540-552.	10.1	292

#	Article	IF	CITATIONS
289	18 F-labeled norepinephrine transporter tracer [18 F]NS12137: radiosynthesis and preclinical evaluation. Nuclear Medicine and Biology, 2018, 56, 39-46.	0.6	7
290	Stress induced neural reorganization: A conceptual framework linking depression and Alzheimer's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 85, 136-151.	4.8	46
291	Zebrafish Mutants Carrying Leptin a (lepa) Gene Deficiency Display Obesity, Anxiety, Less Aggression and Fear, and Circadian Rhythm and Color Preference Dysregulation. International Journal of Molecular Sciences, 2018, 19, 4038.	4.1	54
292	Emotional Roles of Mono-Aminergic Neurotransmitters in Major Depressive Disorder and Anxiety Disorders. Frontiers in Psychology, 2018, 9, 2201.	2.1	126
293	Meta-analysis on the Association Between Norepinephrine Transporter Gene rs2242446, rs5569 Polymorphisms and Risk of Major Depressive Disorder. Archives of Medical Research, 2018, 49, 261-269.	3.3	5
294	α-Synuclein and Noradrenergic Modulation of Immune Cells in Parkinson's Disease Pathogenesis. Frontiers in Neuroscience, 2018, 12, 626.	2.8	28
295	Regulation of monoamine transporters and receptors by lipid microdomains: implications for depression. Neuropsychopharmacology, 2018, 43, 2165-2179.	5.4	29
296	Sex differences in the effect of cannabinoid type 1 receptor deletion on locus coeruleusâ€norepinephrine neurons and corticotropin releasing factorâ€mediated responses. European Journal of Neuroscience, 2018, 48, 2118-2138.	2.6	16
297	Habenular connectivity may predict treatment response in depressed psychiatric inpatients. Journal of Affective Disorders, 2019, 242, 211-219.	4.1	29
298	The contribution of the locus coeruleus-norepinephrine system in the emergence of defeat-induced inflammatory priming. Brain, Behavior, and Immunity, 2019, 79, 102-113.	4.1	33
299	Noradrenergic depletion causes sex specific alterations in the endocannabinoid system in the Murine prefrontal cortex. Neurobiology of Stress, 2019, 10, 100164.	4.0	3
300	Association study of SLC6A2 gene Thr99Ile variant (rs1805065) with athletic status in the Brazilian population. Gene, 2019, 707, 53-57.	2.2	3
301	Recent Trends in the Quantification of Biogenic Amines in Biofluids as Biomarkers of Various Disorders: A Review. Journal of Clinical Medicine, 2019, 8, 640.	2.4	31
302	The Sixth Sense Organs: The Heart. , 2019, , 243-250.		0
303	Modulatory effects of cannabinoids on brain neurotransmission. European Journal of Neuroscience, 2019, 50, 2322-2345.	2.6	64
304	Classifying suicidal behavior with restingâ€state functional connectivity and structural neuroimaging. Acta Psychiatrica Scandinavica, 2019, 140, 20-29.	4.5	41
305	Disabling the Gβγ-SNARE interaction disrupts GPCR-mediated presynaptic inhibition, leading to physiological and behavioral phenotypes. Science Signaling, 2019, 12, .	3.6	33
306	Venlafaxine ER Blocks the Norepinephrine Transporter in the Brain of Patients with Major Depressive Disorder: a PET Study Using [18F]FMeNER-D2. International Journal of Neuropsychopharmacology, 2019, 22, 278-285.	2.1	50

#	Article	IF	CITATIONS
307	Pharmacological manipulations of judgement bias: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2020, 108, 269-286.	6.1	50
308	Unraveling the contributions to the neuromelanin-MRI contrast. Brain Structure and Function, 2020, 225, 2757-2774.	2.3	41
309	Associations Among Monoamine Neurotransmitter Pathways, Personality Traits, and Major Depressive Disorder. Frontiers in Psychiatry, 2020, 11, 381.	2.6	36
310	Structure-Function of the High Affinity Substrate Binding Site (S1) of Human Norepinephrine Transporter. Frontiers in Pharmacology, 2020, 11, 217.	3.5	7
311	Efficacy and safety of 5â€hydroxytryptophan on depression and apathy in Parkinson's disease: a preliminary finding. European Journal of Neurology, 2020, 27, 779-786.	3.3	20
312	Significance? Significance! Empirical, methodological, and theoretical connections between the late positive potential and P300 as neural responses to stimulus significance: An integrative review. Psychophysiology, 2020, 57, e13570.	2.4	181
313	A Novel Function of the Lysophosphatidic Acid Receptor 3 (LPAR3) Gene in Zebrafish on Modulating Anxiety, Circadian Rhythm Locomotor Activity, and Short-Term Memory. International Journal of Molecular Sciences, 2020, 21, 2837.	4.1	6
314	Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms. Pharmacological Reviews, 2021, 73, 202-277.	16.0	110
315	Neurocognitive diseases and disorders. , 2021, , 167-201.		0
316	The rostromedial tegmental nucleus: Features and links with alcohol and depression. , 2021, , 311-321.		0
317	Examining the Role of the Noradrenergic Locus Coeruleus for Predicting Attention and Brain Maintenance in Healthy Old Age and Disease: An MRI Structural Study for the Alzheimer's Disease Neuroimaging Initiative. Cells, 2021, 10, 1829.	4.1	21
318	Integrating the monoamine and cytokine hypotheses of depression: Is histamine the missing link?. European Journal of Neuroscience, 2022, 55, 2895-2911.	2.6	11
319	Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depression and Anxiety, 2000, 12, 2-19.	4.1	510
320	Human Genetics and Pharmacology of Neurotransmitter Transporters. , 2006, , 327-371.		26
321	Sleep disturbances in affective disorders. , 2006, , 101-124.		7
322	Regulation of Biogenic Amine Transporters. , 2007, , 363-386.		2
323	Anatomical Characteristics of Norepinephrine Axons in the Prefrontal Cortex: Unexpected Findings That May Indicate Low Activity State in NaÃīve Animals. , 2007, , 35-65.		2
324	Quantitative Cytoarchitectonic Findings in Postmortem Brain Tissue from Mood Disorder Patients. Neurobiological Foundation of Aberrant Behaviors, 2002, , 291-324.	0.2	1

#	Article	IF	CITATIONS
325	Orexin and Circadian Influences in Sleep and Psychiatric Disorders: A Review of Experimental and Computational Modelling Studies. , 2015, , 299-322.		2
326	Morphological substrates of mental dysfunction in Lewy body disease: an update. , 2000, 59, 185-212.		45
327	Neurobiology of Monoaminergic Neurotransmission and Antidepressants. , 2014, , 321-341.		3
328	Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. , 0, .		9
330	Global Brain Gene Expression Analysis Links Glutamatergic and GABAergic Alterations to Suicide and Major Depression. PLoS ONE, 2009, 4, e6585.	2.5	333
331	Regulation of Monoamine Transporters: Regulated Phosphorylation, Dephosphorylation, and Trafficking. , 0, , 001-023.		4
332	Gene Organization and Polymorphisms of Monoamine Transporters: Relationship to Psychiatric and Other Complex Diseases. , 0, , 111-169.		11
333	Pathophysiology of depression and mechanisms of treatment. Dialogues in Clinical Neuroscience, 2002, 4, 7-20.	3.7	159
334	Cellular abnormalities in depression: evidence from postmortem brain tissue. Dialogues in Clinical Neuroscience, 2004, 6, 185-197.	3.7	47
335	Molecular mechanism of noradrenaline during the stress-induced major depressive disorder. Neural Regeneration Research, 2018, 13, 1159.	3.0	55
336	The Impact of Depression and Apathy on Sensory Language. Open Journal of Modern Linguistics, 2017, 07, 8-32.	0.2	5
337	Calcium signaling cascades, antidepressants and major depressive disorders. , 2001, , 63-79.		0
338	Familial Orthostatic Tachycardia due to Norepinephrine Transporter (SLC6A2) Deficiency. Advances in Behavioral Biology, 2002, , 499-504.	0.2	0
339	Neurobiologische Grundlagen. , 2002, , 1-77.		0
340	Monoamine Receptors in Postmortem Brain: Do Postmortem Brain Studies Cloud or Clarify our Understanding of the Affective Disorders?. Neurobiological Foundation of Aberrant Behaviors, 2002, , 363-385.	0.2	1
342	New Developments in the Regulation of Monoaminergic Neurotransmission. , 2003, , 25-42.		0
343	Effects of Milnacipran on the Inhibitory Postsynaptic Potential in Neurons of the Rat Locus Coeruleus. Kurume Medical Journal, 2004, 51, 185-191.	0.1	1
344	Regulation of Monoamine Transporters: Influence of Psychostimulants and Therapeutic Antidepressants. , 2008, , 247-264.		0

#	Article	IF	CITATIONS
345	Psychiatric diseases. , 2008, , 1153-1195.		0
346	Genetic Regulation of Emotion Brain Circuitries. , 2011, , 108-129.		0
347	Affektive Erkrankungen. , 2012, , 315-324.		0
348	Molekulare Mechanismen der Depressionstherapie. , 1999, , 273-318.		4
352	Shape Deformation in the Brainstem of Medication-NaÃ⁻ve Female Patients with Major Depressive Disorder. Psychiatry Investigation, 2020, 17, 465-474.	1.6	4
353	Norepinephrine Uptake Sites in the Locus Coeruleus of Rat Lines Selectively Bred for High and Low Alcohol Preference: A Quantitative Autoradiographic Binding Study Using [3H]-Tomoxetine. Alcoholism: Clinical and Experimental Research, 2000, 24, 588-594.	2.4	0
354	Radiopharmaceuticals: Recent Developments and Trends. , 2006, , 247-274.		0
355	Lack of association between the norepinephrine transporter gene and major depression in a Han Chinese population. Journal of Psychiatry and Neuroscience, 2007, 32, 121-8.	2.4	31
356	Neurophysiological dynamics for psychological resilience: A view from the temporal axis. Neuroscience Research, 2022, 175, 53-61.	1.9	6
357	Novel Molecular Targets of Antidepressants. Molecules, 2022, 27, 533.	3.8	9
358	Gamma camera imaging in psychiatric disorders. , 2022, , .		0
364	Introductory and Basic Aspects. , 0, , 2-50.		0
365	The Relationships Among Metal Homeostasis, Mitochondria, and Locus Coeruleus in Psychiatric and Neurodegenerative Disorders: Potential Pathogenetic Mechanism and Therapeutic Implications. Cellular and Molecular Neurobiology, 2023, 43, 963-989.	3.3	4
366	Spike-Dependent Dynamic Partitioning of the Locus Coeruleus Network through Noradrenergic Volume Release in a Simulation of the Nucleus Core. Brain Sciences, 2022, 12, 728.	2.3	1
368	Loss of mitochondrial enzyme GPT2 causes early neurodegeneration in locus coeruleus. Neurobiology of Disease, 2022, 173, 105831.	4.4	2
369	Targeting the cannabinoid system to counteract the deleterious effects of stress in Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 14, .	3.4	2
370	Biomarkers For the Diagnosis of Depression: Recent Updates. Current Psychiatry Research and Reviews, 2023, 19, 214-234.	0.2	0
371	Using type-2 fuzzy ontology to improve semantic interoperability for healthcare and diagnosis of depression. Artificial Intelligence in Medicine, 2023, 135, 102452.	6.5	10

#	Article	IF	CITATIONS
372	Development of Post-Stroke Cognitive and Depressive Disturbances: Associations with Neurohumoral Indices. Current Issues in Molecular Biology, 2022, 44, 6290-6305.	2.4	4
373	Priorities for research on neuromodulatory subcortical systems in Alzheimer's disease: Position paper from the NSS PIA of ISTAART. Alzheimer's and Dementia, 2023, 19, 2182-2196.	0.8	11
374	Increased Lactobacillus Abundance Contributes to Stress Resilience in Mice Exposed to Chronic Social Defeat Stress. Neuroendocrinology, 2023, 113, 563-576.	2.5	6
375	Inhibition of norepinephrine signaling during a sensitive period disrupts locus coeruleus circuitry and emotional behaviors in adulthood. Scientific Reports, 2023, 13, .	3.3	2
376	Plausible Role of Stem Cell Types for Treating and Understanding the Pathophysiology of Depression. Pharmaceutics, 2023, 15, 814.	4.5	4
377	Relationships of in vivo brain norepinephrine transporter and age, BMI, and gender. Synapse, 2023, 77, .	1.2	1
378	Acceleration of inferred neural responses to oddball targets in an individual with bilateral amygdala lesion compared to healthy controls. Scientific Reports, 2023, 13, .	3.3	1
380	Imipramine Administration in Brucella abortus 2308-Infected Mice Restores Hippocampal Serotonin Levels, Muscle Strength, and Mood, and Decreases Spleen CFU Count. Pharmaceuticals, 2023, 16, 1525.	3.8	1
381	Evidence for Locus Coeruleus–Norepinephrine System Abnormality in Military Posttraumatic Stress Disorder Revealed by Neuromelanin-Sensitive Magnetic Resonance Imaging. Biological Psychiatry, 2024, , .	1.3	0